Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer
- 1Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China
Abstract
Background: Comparative real-world evidence for camrelizumab plus famitinib versus PD-1 inhibitor plus platinum- and/or taxane-based chemotherapy with or without bevacizumab in persistent, recurrent, or metastatic cervical cancer remains limited. This study evaluated the clinical outcomes and safety of these strategies. Methods: This single-center retrospective cohort study included 111 patients treated between July 2023 and October 2025; 42 received camrelizumab plus famitinib and 69 received the control regimen. Progression-free survival (PFS) was the primary endpoint. Overall survival (OS), tumor response, treatment-related adverse events (TRAEs), propensity score-based robustness analyses, and exploratory post-baseline marker analyses were also assessed. Results: Full-cohort and propensity score-matched Kaplan-Meier analyses showed longer PFS with camrelizumab plus famitinib (p = 0.026 and p = 0.004, respectively). Treatment-effect estimates also favored camrelizumab plus famitinib in unadjusted Cox (p = 0.028), residual imbalance-adjusted Cox (p = 0.041), 1:1 propensity score-matched Cox (p = 0.010), trimmed inverse probability of treatment weighting Cox (p = 0.006), and overlap-weighted Cox analyses (p = 0.005), whereas the prespecified baseline-adjusted Cox model was not statistically significant (p = 0.062). Disease control rate was higher (p = 0.038), grade 3–5 myelosuppression was lower (p = 0.010), and hypertension was higher (p = 0.023) with camrelizumab plus famitinib. OS did not differ significantly. Liver metastasis (p = 0.001) and higher baseline neutrophil-to-lymphocyte ratio (p = 0.037) were associated with shorter PFS. Conclusions: Camrelizumab plus famitinib showed a favorable PFS signal across several analyses, higher disease control, and a distinct safety profile, while the primary baseline-adjusted estimate and OS remained statistically non-significant.
Related
- Camrelizumab plus famitinib as first-line treatment for locally advanced or metastatic pulmonary sarcomatoid carcinomas (CAPSTONE): a multi-center, single-arm, phase 2 trial
- Surufatinib and camrelizumab plus nab-paclitaxel–gemcitabine as first-line treatment for metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
- PF chemotherapy combined with a PD-1/CTLA-4 bispecific antibody as first-line treatment in patients with recurrent/metastatic head and neck squamous cell carcinoma: a prospective, single-arm, phase II clinical study
- Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma
- Recurrent thymoma-associated PRCA with persistent agranulocytosis: a case report and therapeutic considerations
BibTeX
@article{liu2026clinical,
title = {{Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer}},
author = {Xiaojing Liu and Beibei Hua and Yang Xia and Huijie Huang and Areai Hakewati and Zeze Jin and Tumaris Halifu and Zaihua Xu},
journal = {Oncology Research},
year = {2026},
month = oct,
doi = {10.32604/or.2026.088774},
url = {https://doi.org/10.32604/or.2026.088774},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer
AU - Xiaojing Liu
AU - Beibei Hua
AU - Yang Xia
AU - Huijie Huang
AU - Areai Hakewati
AU - Zeze Jin
AU - Tumaris Halifu
AU - Zaihua Xu
PY - 2026
DA - 2026/10/28
JO - Oncology Research
DO - 10.32604/or.2026.088774
UR - https://doi.org/10.32604/or.2026.088774
AB - Background: Comparative real-world evidence for camrelizumab plus famitinib versus PD-1 inhibitor plus platinum- and/or taxane-based chemotherapy with or without bevacizumab in persistent, recurrent, or metastatic cervical cancer remains limited. This study evaluated the clinical outcomes and safety of these strategies. Methods: This single-center retrospective cohort study included 111 patients treated between July 2023 and October 2025; 42 received camrelizumab plus famitinib and 69 received the control regimen. Progression-free survival (PFS) was the primary endpoint. Overall survival (OS), tumor response, treatment-related adverse events (TRAEs), propensity score-based robustness analyses, and exploratory post-baseline marker analyses were also assessed. Results: Full-cohort and propensity score-matched Kaplan-Meier analyses showed longer PFS with camrelizumab plus famitinib (p = 0.026 and p = 0.004, respectively). Treatment-effect estimates also favored camrelizumab plus famitinib in unadjusted Cox (p = 0.028), residual imbalance-adjusted Cox (p = 0.041), 1:1 propensity score-matched Cox (p = 0.010), trimmed inverse probability of treatment weighting Cox (p = 0.006), and overlap-weighted Cox analyses (p = 0.005), whereas the prespecified baseline-adjusted Cox model was not statistically significant (p = 0.062). Disease control rate was higher (p = 0.038), grade 3–5 myelosuppression was lower (p = 0.010), and hypertension was higher (p = 0.023) with camrelizumab plus famitinib. OS did not differ significantly. Liver metastasis (p = 0.001) and higher baseline neutrophil-to-lymphocyte ratio (p = 0.037) were associated with shorter PFS. Conclusions: Camrelizumab plus famitinib showed a favorable PFS signal across several analyses, higher disease control, and a distinct safety profile, while the primary baseline-adjusted estimate and OS remained statistically non-significant.
SN - 0965-0407
SN - 1555-3906
ER -